Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RXRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CMO (new) — The Chief Medical Officer is departing after an undisclosed amount three years in the role, though the structured transition with advisory period suggests a planned change rather than abrupt exit.
Recursion appoints oncology veteran Vicki Goodman as Chief Medical Officer
Filed March 25, 2026 · Period ending March 25, 2026 · ~1 min read
Key Changes
-
high
Vicki Goodman, M.D., joins as CMO effective April 6, 2026, bringing 20+ years oncology drug development experience including senior roles at Exelixis (CMO), Merck (KEYTRUDA late-stage lead), and Bristol Myers Squibb (OPDIVO/YERVOY development lead).
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
David Mauro, M.D., Ph.D., transitions out after an undisclosed amount three years as CMO, continuing in advisory capacity through May 29, 2026 to support the handoff.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Company states pipeline advancement and clinical/regulatory milestones remain consistent with previously communicated expectations, providing context for the planned leadership transition timing.
Exhibit 99.1 view on EDGAR →
Summary
Recursion is replacing its Chief Medical Officer with an experienced oncology drug developer. Vicki Goodman brings deep expertise from senior roles at major oncology franchises — she was CMO at Exelixis, led late-stage KEYTRUDA development at Merck, and oversaw OPDIVO and YERVOY programs at Bristol Myers Squibb.
The appointment comes as Recursion prepares for key clinical and regulatory milestones the company says remain on track with prior guidance. David Mauro's departure after three years raises the question of why the company is changing medical leadership now, particularly given his role in advancing the clinical portfolio including REC-4881.
However, the structured transition — Mauro remains in an advisory role through late May — suggests a planned succession rather than a sudden exit. For a clinical-stage biotech, CMO continuity matters for trial execution and regulatory strategy. Investors should watch whether Goodman's oncology focus signals a strategic shift in pipeline priorities or simply reflects her background as Recursion advances its existing programs.
Section-by-Section Diff
Event · Exhibit 99.1
Recursion appoints Vicki Goodman, M.D., as Chief Medical Officer effective April 6, 2026, replacing David Mauro, M.D., Ph.D.
Added in current filing · view on EDGAR →
Recursion’s current CMO, David Mauro, M.D., Ph.D. will be transitioning from his role after approximately three years.
David Mauro is leaving the Chief Medical Officer position after an undisclosed amount three years. The company thanked him for strengthening the medical organization, guiding the clinical portfolio advancement, and supporting milestones including the progression of REC-4881. The transition appears planned and coordinated with the incoming CMO appointment.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Recursion appoints Vicki Goodman as Chief Medical Officer effective April 6, 2026, replacing David Mauro who transitions to advisory role.
Added in current filing · verify on EDGAR →
Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026, as David Mauro, M.D., Ph.D. transitions out of the role. In connection with his departure, Dr. Mauro will continue to serve the Company in an advisory capacity for a transitional period until May 29, 2026.
The company is replacing its Chief Medical Officer. Dr. Vicki Goodman will assume the CMO role on April 6, 2026, while outgoing CMO Dr. David Mauro will remain in an advisory capacity through May 29, 2026. This appears to be a planned transition rather than an abrupt departure, as evidenced by the transitional advisory period.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 22, 2026 · How we verify